Response to treatment at 12 weeks, 3 months, and 1 year after treatment
| Time after treatment . | ATG + CyA, no. (%) . | ATG + CyA + G-CSF, no. (%) . | P . |
|---|---|---|---|
| 12 weeks | |||
| No. of patients evaluable | 47 | 48 | — |
| CR | 2 | 0 | — |
| PR | 22 | 28 | — |
| Total response, CR+PR | 24 (51) | 28 (58) | .31 |
| Death | 0 | 2 | — |
| 6 months | |||
| No. of patients evaluable | 46 | 47 | — |
| CR | 3 | 2 | — |
| PR | 23 | 34 | — |
| Total response, CR+PR | 26 (57) | 36 (77) | .03 |
| Death | 0 | 2 | — |
| 1 year | |||
| No. of patients evaluable | 41 | 47 | — |
| CR | 1 | 3 | — |
| PR | 30 | 34 | — |
| Total response, CR+PR | 31 (76) | 37 (79) | .46 |
| Death | 1 | 2 | — |
| Time after treatment . | ATG + CyA, no. (%) . | ATG + CyA + G-CSF, no. (%) . | P . |
|---|---|---|---|
| 12 weeks | |||
| No. of patients evaluable | 47 | 48 | — |
| CR | 2 | 0 | — |
| PR | 22 | 28 | — |
| Total response, CR+PR | 24 (51) | 28 (58) | .31 |
| Death | 0 | 2 | — |
| 6 months | |||
| No. of patients evaluable | 46 | 47 | — |
| CR | 3 | 2 | — |
| PR | 23 | 34 | — |
| Total response, CR+PR | 26 (57) | 36 (77) | .03 |
| Death | 0 | 2 | — |
| 1 year | |||
| No. of patients evaluable | 41 | 47 | — |
| CR | 1 | 3 | — |
| PR | 30 | 34 | — |
| Total response, CR+PR | 31 (76) | 37 (79) | .46 |
| Death | 1 | 2 | — |
— indicates not applicable.